Atypical antipsychotic with opioid antagonist

This page covers all Atypical antipsychotic with opioid antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine receptors, serotonin receptors (olanzapine); mu-opioid receptor (samidorphan), D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor.

Targets

Dopamine receptors, serotonin receptors (olanzapine); mu-opioid receptor (samidorphan) · D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor

Marketed (2)

• Olanzapine-samidorphan + exercise · New York State Psychiatric Institute · Psychiatry
  Olanzapine-samidorphan combines an atypical antipsychotic (olanzapine) with a mu-opioid receptor antagonist (samidorphan) to treat schizophrenia and bipolar disorder while mitigating weight gain, with exercise as a behavioral intervention.
• LYBALVI · Alkermes, Inc. · Psychiatry
  LYBALVI is a combination of lurasidone (an atypical antipsychotic) and samidorphan (an opioid antagonist) that blocks dopamine and serotonin receptors while antagonizing opioid receptors to reduce antipsychotic-induced weight gain.